Provectus Biopharmaceuticals (Provectus Biopharmaceuticals) Total Inventories : $0.00 Mil (As of Dec. 2023)

View and export this data going back to 1997. Start your Free Trial

What is Provectus Biopharmaceuticals Total Inventories?

Provectus Biopharmaceuticals's total inventories for the quarter that ended in Dec. 2023 was $0.00 Mil. Provectus Biopharmaceuticals's average total inventories from the quarter that ended in Sep. 2023 to the quarter that ended in Dec. 2023 was $0.00 Mil.

In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Provectus Biopharmaceuticals's Net-Net Working Capital per share for the quarter that ended in Dec. 2023 was $-0.02.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Inventory Turnover measures how fast the company turns over its inventory within a year.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Provectus Biopharmaceuticals Total Inventories Historical Data

The historical data trend for Provectus Biopharmaceuticals's Total Inventories can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Provectus Biopharmaceuticals Total Inventories Chart

Provectus Biopharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Inventories

Get a 7-Day Free Trial

Provectus Biopharmaceuticals Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Total Inventories	Get a 7-Day Free Trial															-	-	-	-	-

Provectus Biopharmaceuticals Total Inventories Calculation

Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.

Provectus Biopharmaceuticals (OTCPK:PVCT) Total Inventories Explanation

Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.

1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.

Provectus Biopharmaceuticals's Net-Net Working Capital Per Share for the quarter that ended in Dec. 2023 is

	Net-Net Working Capital Per Share (Q: Dec. 2023 )
=	(Cash And Cash Equivalents	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(0.077	+	0.75 * 0	+	0.5 * 0	-	9.042
-	0.023	-	0)	/	419.522
=	-0.02

2. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Provectus Biopharmaceuticals's Days Inventory for the three months ended in Dec. 2023 is calculated as:

Days Inventory	=	Average Total Inventories (Q: Dec. 2023 )	/	Cost of Goods Sold (Q: Dec. 2023 )	*	Days in Period
	=	0	/	0	*	365 / 4
	=

3. Inventory Turnover measures how fast the company turns over its inventory within a year.

Provectus Biopharmaceuticals's Inventory Turnover for the quarter that ended in Dec. 2023 is calculated as

Inventory Turnover	=	Cost of Goods Sold (Q: Dec. 2023 )	/	Average Total Inventories (Q: Dec. 2023 )
	=	0	/	0
	=	N/A

4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Provectus Biopharmaceuticals's Inventory to Revenue for the quarter that ended in Dec. 2023 is calculated as

Inventory-to-Revenue	=	Average Total Inventories (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	0	/	0
	=

Be Aware

Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.

When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.

Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.

Provectus Biopharmaceuticals Total Inventories Related Terms

Thank you for viewing the detailed overview of Provectus Biopharmaceuticals's Total Inventories provided by GuruFocus.com. Please click on the following links to see related term pages.

Provectus Biopharmaceuticals (Provectus Biopharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Provectus Biopharmaceuticals Inc (OTCPK:PVCT) » Definitions » Total Inventories

Comparable Companies

Traded in Other Exchanges

N/A

Address

800 S Gay St, Suite 1610, Knoxville, TN, USA, 37932

Website

https://www.provectusbio.com

Provectus Biopharmaceuticals Inc is a is a clinical-stage biotechnology company. It is engaged in developing ethical pharmaceuticals for oncology and dermatology indications. The company has developed and intends to license or market and sell its two prescription drug candidates, PV-10 and PH-10. Its PV-10 is for the treatment of several life-threatening cancers including metastatic melanoma, liver cancer, and breast cancer. The PH-10 is to provide minimally invasive treatment of chronic severe skin afflictions such as psoriasis and atopic dermatitis, a type of eczema.

Executives

Jeffrey Allen Morris	10 percent owner	1729 TRIANGLE PARK DR., MARYVILLE TN 37801
Webster Bailey	director	10025 INVESTMENT DRIVE, SUITE 250, KNOXVILLE TN 37932
Heather Raines	officer: Chief Financial Officer	10025 INVESTMENT DRIVE, SUITE 250, KNOXVILLE TN 37932
Edward Pershing	director	2220 SOUTHERLAND AVE, KNOXVILLE TN 37919
John Iii Lacy	director	10025 INVESTMENT DRIVE, SUITE 250, KNOXVILLE TN 37932
John R Glass	officer: See Remarks	7327 OAK RIDGE HIGHWAY SUITE A, KNOXVILLE TN 37931
Bruce Horowitz	director	7327 OAK RIDGE HIGHWAY, KNOXVILLE TN 37931
Dominic Rodrigues	director	7327 OAK RIDGE HIGHWAY, KNOXVILLE TN 37931
Peter R Culpepper	officer: Interim CEO, CFO, COO	7327 OAK RIDGE HWY, SUITE A, OAK RIGE TN 37931
Eric Phd Wachter	director, officer: Chief Technology Officer	PROVECTUS PHARMACEUTICALS INC, 7327 OAK RIDGE HIGHWAY, KNOXVILLE TN 37931
Jan Koe	director	7327 OAK RIDGE HIGHWAY, KNOXVILLE TN 37931
Smith Alfred E. Iv	director	191 MAIN STREET, NEW CANAAN CT 06840
Kelly M Mcmasters	director	7327 OAK RIDGE HIGHWAY, KNOXVILLE TN 37931
Donald E Adams	10 percent owner	370 CRESTMONT DRIVE, SAN LUIS OBISPO CA 93401
Timothy Phd Scott	director, 10 percent owner, officer: President	PROVECTUS PHARMACEUTICALS INC, 7327 OAK RIDGE HIGHWAY, KNOXVILLE TN 37931